Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital Identifier:
First received: December 1, 2013
Last updated: December 26, 2013
Last verified: December 2013

For gastric patients of Karnofsky scores between 60-80 scores, mFolfox6 is an option for chemotherapy. Neutropenia and oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in discontinue of chemotherapy, especially for patients suffered from heavily acute neurotoxicity. Monosialotetrahexosylganglioside is a component of membrane of nerve cells. Previous phase II clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(OIN). But it did not certificated by phase III trial. A phase III trial is needed to investigate the effect and safety of monosialotetrahexosylganglioside Sodium Injection for prevention OIN at gastric cancer.

Condition Intervention Phase
Gastric Cancer
Drug: monosialotetrahexosylganglioside Sodium
Other: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Gastric Cancer

Resource links provided by NLM:

Further study details as provided by Tianjin Medical University Cancer Institute and Hospital:

Primary Outcome Measures:
  • The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity [ Time Frame: From the first day of chemotherapy to 12 months after study or until one week before the patients receive second-line chemotherapy ] [ Designated as safety issue: Yes ]
    acute neurotoxicity will be assessed the first day of oxaliplatin at every cycle given;accumulating neurotoxicity will be assessed every two weeks from the second day of first cycle until the patients out of the study. The accumulating neurotoxicity will be assessed every four weeks for 12 months or one week before second-line chemotherapy

Secondary Outcome Measures:
  • Objective response rate [ Time Frame: Eevery 6 weeks, up to 24 months ] [ Designated as safety issue: No ]
    investigators assess the effect every six weeks and objective response is recorded as complete response,partial response or stable disease according to Recist 1.1

  • Progress Free Survival [ Time Frame: investigators assess the effect of chemotherapy every 6 weeks ,up to 24 months ] [ Designated as safety issue: No ]
    From date of randomization until the date of first documented progression

  • overall Survival [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 100 months ] [ Designated as safety issue: No ]
    the patients will be followed one month after progression ,then every 3 months,up to 100 months

  • quality of life [ Time Frame: evaluate 1 week before chemotherapy and every 6 weeks of study. And evaluate within 4 weeks after the patients out of the study ] [ Designated as safety issue: No ]
    investigators use sf-36 to evaluated the quality of life

Estimated Enrollment: 240
Study Start Date: December 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
Other: placebo
saline of the same appearance as monosialotetrahexosylganglioside Sodium
Other Name: saline
Experimental: monosialotetrahexosylganglioside Sodium
arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
Drug: monosialotetrahexosylganglioside Sodium
it is extracted from pig's brain,shenjie is the brand name
Other Name: brand name : shenjie

Detailed Description:

it is a placebo controlled phase III trial. Investigators plan to enroll 240 patients with 1:1 to A arm and B arm


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients shall have normal organic function such as liver function, Cardiac function and renal function;
  2. age >18 years old;
  3. diagnosis metastatic colorectal cancer with histology;
  4. Did not received first-line chemotherapy
  5. Karnofsky Performance scores should be 60,70,or80
  6. should have target lesions or non-target lesions
  7. For patients received oxaliplatin before, the residual neurotoxicity should less than grade 2
  8. For diabetes without neuropathy, blood glucose before meal should less than 8mmol/L and HBA1C<7.0%
  9. Patients should be expected to live no shorter than 3 months

Exclusion Criteria:

  1. patients who is receiving chemotherapy;
  2. WBC<4.0×109/L,ANC<1.5×109/L,PLT<100×109/L,Hb<90g/L,TBIL>1.5Limitation;BUN)>1.5Limitation;Cr)>1.5Limitation;ALT or AST>2.5Limitation(without liver metastasis);ALT or AST)>5Limitation(with liver metastasis);
  3. heart dysfunction;
  4. brain metastasis;
  5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy;
  6. patients who received Glutathione, acetylcysteine, calcium / magnesium, amifostine, carbamazepine, B vitamins, vitamin E within 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02024438

China, Tianjin
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin, China, 300060
Sponsors and Collaborators
Tianjin Medical University Cancer Institute and Hospital
Study Director: Yi Ba, MD.PHD Tianjin Medical University Cancer Institute and Hospital
  More Information

No publications provided

Responsible Party: Tianjin Medical University Cancer Institute and Hospital Identifier: NCT02024438     History of Changes
Other Study ID Numbers: 20131201
Study First Received: December 1, 2013
Last Updated: December 26, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by Tianjin Medical University Cancer Institute and Hospital:
metastatic gastric cancer
monosialotetrahexosylganglioside Sodium Injection

Additional relevant MeSH terms:
Neurotoxicity Syndromes
Stomach Neoplasms
Chemically-Induced Disorders
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Site
Nervous System Diseases
Stomach Diseases processed this record on August 26, 2015